Startseite>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Monocarboxylate Transporters>>BAY-8002

BAY-8002

Katalog-Nr.GC19488

BAY-8002 ist ein potenter, selektiver, oral aktiver Inhibitor des Monocarboxylat-Transporters 1 (MCT1) mit einem IC50-Wert von 85 nM in den MCT1-exprimierenden DLD-1-Zellen und zeigt eine hervorragende Selektivität gegenüber MCT4. Anti-Tumor-Aktivität.

Products are for research use only. Not for human use. We do not sell to patients.

BAY-8002  Chemische Struktur

Cas No.: 724440-27-1

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
78,00 $
Auf Lager
5mg
71,00 $
Auf Lager
10mg
126,00 $
Auf Lager
10mg
126,00 $
Auf Lager
50mg
378,00 $
Auf Lager
50mg
378,00 $
Auf Lager
100mg
648,00 $
Auf Lager
100mg
648,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

BAY-8002 is a potent, selective, orally active inhibitor of monocarboxylate transporter 1 (MCT1), with an IC50 of 85 nM in the MCT1-expressing DLD-1 cells, displays excellent selectivity against MCT4. Anti-tumor activity[1].

BAY-8002 is an inhibitor of MCT1, with an IC50 of 85 nM in the MCT1-expressing DLD-1 cells, displays excellent selectivity against MCT4 (IC50 >50 µM in EVSA-T cells)[1].

Reference:

[1]. Quanz M, et al. Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance. Mol Cancer Ther. 2018 Nov;17(11):2285-2296.

Bewertungen

Review for BAY-8002

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BAY-8002

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.